Posts tagged: multiple

Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease Maureen A.

Brain Lesions May Serve as Diagnostic Criteria for Neuromyelitis Optica 2011;19(8):13. A majority of patients with neuromyelitis optica also experience disease-specific brain lesions that could help distinguish neuromyelitis optica from multiple sclerosis. MONTREAL—Imaging studies of patients with neuromyelitis optica (NMO)–spectrum disorders reveal that effects of the aquaporin-4 (AQP4) autoantibody, a marker of the disease, may extend beyond the spinal cord and optic nerve, according to researchers

Association Between Paroxysmal Tonic Spasms and Neuromyelitis Optica Nida Usmani, MD; Gurdesh Bedi, MD; Byron L. Lam, MD; William A

MS-Related Disorders ID’d by Proteomic Pattern Analysis Last Updated: September 19, 2011. CSF proteomic pattern analysis discriminates among multiple sclerosis-related disorde Proteomic pattern analysis of cerebrospinal fluid analysis using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry distinguishes between similar multiple sclerosis-related disorders, according to a study published online Sept.

Markedly Elevated Soluble Intercellular Adhesion Molecule 1, Soluble Vascular Cell Adhesion Molecule 1 Levels, and Blood-Brain Barrier Breakdown in Neuromyelitis Optica Akiyuki Uzawa, MD; Masahiro Mori, MD, PhD; Saeko Masuda, MD; Satoshi Kuwabara, MD, PhD Arch Neurol. ?2011;68(7):913-917.

Multiple sclerosis: pathology and pathogenesis Monday, May 30, 2011, 17:15 – 18:15 The pathology of fulminant neuromyelitis optica with extremely high level of serum anti aquaporin 4 antibody K. Maruyama, M.

In 1894, Eug?ne Devic (1858–1930) described a 45-year-old female hatter in whom ‘l’autopsie r?v?la l’existence d’un foyer de my?lite aigu? diffuse localis?e ? la r?gion du renflement lombaire et d’une n?vrite optique double bien marqu?e’ … the autopsy showed a focus of acute diffuse myelitis localized to the lumbar enlargement, as well as a distinct bilateral optic neuritis (Devic, 1894 ). He called the condition ‘neuromy?lite optique aig?e’

Purpose: To prospectively assess sensitivity and specificity of diffusion indexes of the corpus callosum (CC) for differentiating relapsing neuromyelitis optica (RNMO) from relapsing-remitting multiple sclerosis (RRMS), by using final clinical diagnosis as the reference standard. Materials and Methods: Participants provided informed consent; the study was approved by the institutional review board. Forty-six consecutive patients with RRMS (18 men, 28 women; mean age, 37.7 years; range, 18–58 years) and 26 consecutive patients with RNMO (two men, 24 women; mean age, 38.6 years; range, 19–59 years) underwent diffusion-tensor magnetic resonance imaging.

? NARCOMS Report-2007 Registry Update Optic Neuritis in Multiple Sclerosis ? Neuromyelitis Optica Dean M. Wingerchuk, MD, MSc, FRCP(C) A Historical Perspective on NMO Neuromyelitis optica (NMO), also known as Devic’s disease, was identified more than one hundred years ago as a severe disorder affecting the spinal cord (causing paralysis) and both optic nerves (causing blindness).

BACKGROUND: Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFNbeta) in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: We conducted a post hoc analysis of data from the Safety and Efficacy of Natalizumab in Combination With IFNbeta-1a in Patients With Relapsing-Remitting Multiple Sclerosis (SENTINEL) study to determine the effects of statins on efficacy of IFNbeta. SENTINEL was a prospective trial of patients with RRMS treated with natalizumab (Tysabri, Biogen Idec, Inc., Cambridge, MA) plus IM IFNbeta-1a (Avonex, Biogen Idec, Inc.) 30 microg compared with placebo plus IM IFNbeta-1a 30 microg.

The availability of natalizumab for the treatment of multiple sclerosis has revolutionised the practice of neurology in at least one salient way: we now spend much more time thinking about progressive multifocal leukoencephalopathy (PML). The reasons for this increased attention are not difficult to identify

OBJECTIVE: To evaluate the degree of blood-brain barrier disruption in patients with neuromyelitis optica (NMO) and to clarify whether the levels of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) in patients with NMO can be useful biomarkers for blood-brain barrier breakdown.